NCT03965494View on ClinicalTrials.gov

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

BGB 324 (before surgery)

Given by mouth either BEFORE therapeutic conventional surgery

DRUG

BGB 324 (after surgery)

Given by mouth either AFTER therapeutic conventional surgery

Trial Locations (6)

10065

Memorial Sloan Kettering, New York

19104

University of Pennsylvania, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27157

Wake Forest University Comprehensive Cancer Center, Winston-Salem

35294

Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham

48202

Henry Ford Hospital, Detroit

Sponsors

Collaborators (1)

BerGenBio ASA
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

BerGenBio ASA

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03965494 - AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | Biotech Hunter | Biotech Hunter